
    
      Summary:

      The CVRx BAROSTIM THERAPY in Heart Failure with Reduced Ejection Fraction (HFrEF) Registry
      includes patients who have been recently implanted with the BAROSTIM NEO System for heart
      failure. Up to 5,000 patients will be enrolled. Patients must be enrolled within 30 days
      after the implant. Data should be obtained from standard of care measurements taken prior to
      implant, at implant, and every six months after device implant, up to the 36-month visit at
      which time each patient will be exited from the registry.
    
  